ResMed Stock Forecast, Price & News

ResMed (NYSE:RMD) Frequently Asked Questions

Is ResMed a buy right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 2 sell ratings, 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ResMed stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RMD, but not buy additional shares or sell existing shares.
View analyst ratings for ResMed or view top-rated stocks.

What stocks does MarketBeat like better than ResMed?

Wall Street analysts have given ResMed a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ResMed wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is ResMed's next earnings date?

ResMed is scheduled to release its next quarterly earnings announcement on Thursday, October 28th 2021.
View our earnings forecast for ResMed.

How can I listen to ResMed's earnings call?

ResMed will be holding an earnings conference call on Thursday, October 28th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 201-612-7415 with passcode "13723324".

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) announced its quarterly earnings results on Thursday, August, 5th. The medical equipment provider reported $1.35 earnings per share for the quarter, beating the consensus estimate of $1.25 by $0.10. The medical equipment provider earned $876.10 million during the quarter, compared to analysts' expectations of $781.10 million. ResMed had a net margin of 14.84% and a trailing twelve-month return on equity of 28.03%. During the same quarter in the prior year, the firm posted $1.33 earnings per share.
View ResMed's earnings history.

How has ResMed's stock been impacted by COVID-19 (Coronavirus)?

ResMed's stock was trading at $153.61 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RMD shares have increased by 74.1% and is now trading at $267.50.
View which stocks have been most impacted by COVID-19.

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed announced a quarterly dividend on Thursday, August 5th. Investors of record on Thursday, August 19th will be paid a dividend of $0.42 per share on Thursday, September 23rd. This represents a $1.68 dividend on an annualized basis and a dividend yield of 0.63%. The ex-dividend date of this dividend is Wednesday, August 18th. This is an increase from ResMed's previous quarterly dividend of $0.39.
View ResMed's dividend history.

Is ResMed a good dividend stock?

ResMed pays an annual dividend of $1.68 per share and currently has a dividend yield of 0.66%. ResMed does not yet have a strong track record of dividend growth. The dividend payout ratio of ResMed is 31.52%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ResMed will have a dividend payout ratio of 25.19% next year. This indicates that ResMed will be able to sustain or increase its dividend.
View ResMed's dividend history.

What price target have analysts set for RMD?

12 brokers have issued twelve-month price targets for ResMed's stock. Their forecasts range from $210.00 to $270.00. On average, they anticipate ResMed's stock price to reach $241.50 in the next year. This suggests that the stock has a possible downside of 9.7%.
View analysts' price targets for ResMed or view top-rated stocks among Wall Street analysts.

Who are ResMed's key executives?

ResMed's management team includes the following people:

• Mick Farrell, Chief Executive Officer & Director
• Rob Douglas, President & Chief Operating Officer
• Brett A. Sandercock, Chief Financial Officer
• Carlos M. Nunez, Chief Medical Officer
• Bobby Ghoshal, Chief Technology Officer & President-SaaS Business

What is Mick Farrell's approval rating as ResMed's CEO?

284 employees have rated ResMed CEO Mick Farrell on Glassdoor.com. Mick Farrell has an approval rating of 92% among ResMed's employees. This puts Mick Farrell in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of ResMed's key competitors?

Some companies that are related to ResMed include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Edwards Lifesciences (EW), Becton, Dickinson and (BDX), Boston Scientific (BSX), IDEXX Laboratories (IDXX), DexCom (DXCM), Baxter International (BAX), STERIS (STE), Insulet (PODD), Hologic (HOLX), Teleflex (TFX) and Abiomed (ABMD).
View all of RMD's competitors.

What other stocks do shareholders of ResMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include NVIDIA (NVDA), The Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE), Visa (V), Alibaba Group (BABA), PayPal (PYPL) and QUALCOMM (QCOM).

What is ResMed's stock symbol?

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

Who are ResMed's major shareholders?

ResMed's stock is owned by many different retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (1.96%), Welch & Forbes LLC (0.21%), Capital Investment Services of America Inc. (0.09%), Tandem Investment Advisors Inc. (0.08%), Frontier Capital Management Co. LLC (0.07%) and Chevy Chase Trust Holdings Inc. (0.06%). Company insiders that own ResMed stock include Brett Sandercock, Dave Michaud, David Pendarvis, James Hollingshead, Justin Leong, Michael J Farrell, Rajwant Sodhi, Richard Mchale, Robert Andrew Douglas and Ronald R Taylor.
View institutional ownership trends for ResMed.

Which institutional investors are selling ResMed stock?

RMD stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Nisa Investment Advisors LLC, Frontier Capital Management Co. LLC, Crossmark Global Holdings Inc., Capital Investment Services of America Inc., Telos Capital Management Inc., MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH, and Chevy Chase Trust Holdings Inc.. Company insiders that have sold ResMed company stock in the last year include Brett Sandercock, Dave Michaud, David Pendarvis, James Hollingshead, Justin Leong, Rajwant Sodhi, Robert Andrew Douglas, and Ronald R Taylor.
View insider buying and selling activity for ResMed or view top insider-selling stocks.

Which institutional investors are buying ResMed stock?

RMD stock was purchased by a variety of institutional investors in the last quarter, including Tandem Investment Advisors Inc., FNY Investment Advisers LLC, Assenagon Asset Management S.A., Pensionfund DSM Netherlands, Oak Harvest Investment Services, Diamant Asset Management Inc., Highland Private Wealth Management, and Private Advisor Group LLC.
View insider buying and selling activity for ResMed or or view top insider-buying stocks.

How do I buy shares of ResMed?

Shares of RMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ResMed's stock price today?

One share of RMD stock can currently be purchased for approximately $267.50.

How much money does ResMed make?

ResMed has a market capitalization of $38.97 billion and generates $3.20 billion in revenue each year. The medical equipment provider earns $474.51 million in net income (profit) each year or $5.33 on an earnings per share basis.

How many employees does ResMed have?

ResMed employs 7,770 workers across the globe.

When was ResMed founded?

ResMed was founded in 1989.

What is ResMed's official website?

The official website for ResMed is www.resmed.com.

Where are ResMed's headquarters?

ResMed is headquartered at 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123.

How can I contact ResMed?

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at (858) 836-5000 or via email at [email protected].